The worlds most advanced malaria vaccine, MosquirixTM, produced by Glaxo Smith Kline plc (GSK) could start to be rolled out in Africa within 12 months. You can see the full press release from GSK on their website
The vaccine is aimed at young children and has received a positive response from the European Medicines Agency’s Committee for Medicinal Products for Human Use last week. But the eventual roll-out of the vaccine in sub-Saharan Africa is dependent on a number of factors, not least decisions from the World Health Organization, individual governments and the Vaccines Alliance (GAVI), which is expected to subsidise the immunization programs.
Regardless of the obstacles to yet be overcome, this breakthrough in research is fantastic news and may save many lives in Kenya. So we welcome this development from GSK and look forward to both government and funding approval as soon as possible.
